SCHEMBL15613501

SCHEMBL15613501

Cc1ncc(COc2cc(F)cc(Oc3ccc(-c4nn(CC(C)(C)O)c5ncnc(N)c45)cc3)c2)s1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPK1 P28482 3/20 0.46
▸ CYP1A2 P05177 2/20 0.46
▸ KDM4E B2RXH2 1/20 0.46
▸ TP53 P04637 1/20 0.46
▸ CYP3A4 P08684 1/20 0.46
▸ BTK Q06187 13/20 0.46
▸ PRKD3 O94806 1/20 0.44
▸ MEN1 O00255 1/20 0.43
▸ KMT2A Q03164 1/20 0.43
▸ TDP1 Q9NUW8 1/20 0.43
▸ RET P07949 3/20 0.42
▸ SRC P12931 5/20 0.41
▸ ABL1 P00519 1/20 0.41
▸ FYN P06241 5/20 0.41
▸ LYN P07948 4/20 0.41
▸ FLT3 P36888 4/20 0.41
▸ PTK6 Q13882 4/20 0.41
▸ HCK P08631 3/20 0.41
▸ FGR P09769 3/20 0.41
▸ MAP2K1 Q02750 3/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16886189 0.91 MAPK1 (0.47) MAPK1CYP1A2KDM4ETP53CYP3A4
SCHEMBL15613521 0.89 SRC (0.47) MAPK1BTKRETSRCABL1
SCHEMBL15613676 0.88 BTK (0.44) MAPK1BTKRETSRCABL1
SCHEMBL15613566 0.88 KDM4E (0.55) CYP1A2KDM4EBTKPRKD3RET
SCHEMBL15613564 0.88 BTK (0.49) MAPK1CYP1A2KDM4ETP53CYP3A4
SCHEMBL15613749 0.86 NUDT14 (0.56) BTKSRCABL1HCKAURKA
SCHEMBL15613537 0.86 CYP1A2 (0.47) MAPK1CYP1A2KDM4ETP53CYP3A4
SCHEMBL15613665 0.85 SRC (0.49) BTKRETSRCABL1FYN
SCHEMBL15613656 0.85 CYP1A2 (0.46) MAPK1CYP1A2KDM4ETP53CYP3A4
SCHEMBL16886190 0.85 CYP1A2 (0.47) MAPK1CYP1A2KDM4ETP53CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9796716-B2 Selective inhibitors of Tec and Src protein kinase families PHARMASCIENCE, INC. (CA) 2017-10-24 — — US disclosed
US-9796716-B2 Selective inhibitors of Tec and Src protein kinase families PHARMASCIENCE, INC. (CA) 2017-10-24 — — US disclosed
US-20150191473-A1 PROTEIN KINASE INHIBITORS PHARMASCIENCE, INC. (CA) 2015-07-09 — — US disclosed
US-20150191473-A1 PROTEIN KINASE INHIBITORS PHARMASCIENCE, INC. (CA) 2015-07-09 — — US disclosed
WO-2013177668-A1 PROTEIN KINASE INHIBITORS PHARMASCIENCE, INC. (CA) 2013-12-05 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150191473-A1 PROTEIN KINASE INHIBITORS TEC, SRC, LCK MAPK1 159/4885CYP1A2 4734/4885KDM4E 1338/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback